ClinicaliQ Trial Snapshot
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer — Active Not Recruiting • Phase II • Oncology • NCT02711553.
- Trial testing two new drugs combined with standard chemotherapy for advanced biliary tract cancer to assess effectiveness and safety.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer. Conditions: Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer Interventions: Ramucirumab, Merestinib, Cisplatin, Gemcitabine, Placebo Oral, Placebo IV Lead Sponsor: Eli Lilly and Company Planned Enrollment: 309 participants